专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20070166331A1 Modified seb and prophylactics/remedies for immunopathy containing the same 失效
标题翻译：用于含有其的免疫疾病的修饰型和预防药物/补救剂
公开(公告)号：US20070166331A1
公开(公告)日：2007-07-19
申请号：US10551263
申请日：2003-03-28
申请人： Toshihiro Nakashima , Takumi Sasaki , Kazuhiko Kimachi , Shigeki Kuwata , Tsukasa Nishihara , Atsuko Sakata , Masao Ohkuchi , Tomoyuki Koshi , Toshiyuki Edano
发明人： Toshihiro Nakashima , Takumi Sasaki , Kazuhiko Kimachi , Shigeki Kuwata , Tsukasa Nishihara , Atsuko Sakata , Masao Ohkuchi , Tomoyuki Koshi , Toshiyuki Edano
IPC分类号： A61K39/09 , C07K14/31
CPC分类号： A61K38/164 , C07K14/31 , C07K16/1271
摘要： A novel prophylactic/remedy for immunopathy is provided which is not neutralized by a neutralizing antibody to Staphylococcal enterotoxin B (SEB), known as one of superantigens, and may effectively act as a superantigen. A modified SEB having a reduced reactivity with a neutralizing antibody to SEB (anti-SEB antibody) and a prophylactic/remedy for immunopathy comprising as an active ingredient said modified SEB. The modified SEB of the present invention may be prepared with the evolutionary molecular engineering technique by introducing amino acid substitution in the amino acid sequence of SEB, especially at an epitope recognition site of the anti-SEB antibody in the amino acid sequence of SEB.
摘要翻译：提供一种免疫病的新型预防/治疗方法，其不被被称为超抗原之一的葡萄球菌肠毒素B（SEB）的中和抗体中和，并且可以有效地作为超抗原。与SEB中和抗体（抗SEB抗体）具有降低的反应性的修饰SEB和用于免疫病的预防/治疗方法，其包含所述经修饰的SEB作为活性成分。本发明的经修饰的SEB可以通过在SEB的氨基酸序列中引入氨基酸取代，特别是在SEB的氨基酸序列中的抗SEB抗体的表位识别位点处进行进化分子工程技术来制备。

12. 发明授权

US07132243B2 Clonal expansion of T cells of unknown specificity and identification of ligand recognized by the clonally expanded T cells 有权
标题翻译：未知特异性T细胞的克隆扩增和克隆扩增的T细胞识别的配体的鉴定
公开(公告)号：US07132243B2
公开(公告)日：2006-11-07
申请号：US09962445
申请日：2001-09-26
申请人： Sho Matsushita , Toshihiro Nakashima
发明人： Sho Matsushita , Toshihiro Nakashima
IPC分类号： G01N33/53 , G01N33/566 , C12N5/08
CPC分类号： C12N5/0636 , C12N2501/23 , C12N2501/58 , C12N2503/00 , G01N33/505
摘要： A process for clonally expanding T cells of unknown specificity and a process for identifying a peptide ligand recognized by said T cells are provided.A process for clonally expanding T cells of unknown specificity which comprises co-culturing said T cells of unknown specificity with combinatorial randomized peptide library (Xn peptide library wherein n is a number of amino acids) consisted of peptides having a randomized amino acid sequence consisted of amino acid residues selected from nineteen kinds of naturally occurring amino acid other than cysteine, an interleukin, and major histocompatibility complex (MHC) class II antigen-expressing cells with DNA synthesis being suspended, said cells being derived from the individual where said T cells are obtained; and a process for identifying a peptide ligand recognized by the T cell clone of unknown specificity obtained by said process, which comprises determining proliferating activity of said T cell clone with Xn peptide library, in the presence of an interleukin and MHC class II antigen-expressing cells with DNA synthesis being suspended, said cells being derived from the individual where said T cells are obtained, to thereby determine a peptide sequence that can activate proliferation of T cells.
摘要翻译：提供了用于克隆扩增未知特异性的T细胞的方法和用于鉴定所述T细胞识别的肽配体的方法。一种用于克隆扩增未知特异性的T细胞的方法，其包括由具有随机化氨基酸序列的肽组成的组合随机肽文库（Xn肽文库，其中n为多个氨基酸）共同培养所述具有未知特异性的T细胞选自十九种除了半胱氨酸之外的天然存在的氨基酸，白细胞介素和悬浮有DNA合成的主要组织相容性复合体（MHC）II类抗原表达细胞的氨基酸残基，所述细胞衍生自所述T细胞的个体获得; 以及用于鉴定由所述方法获得的未知特异性的T细胞克隆识别的肽配体的方法，其包括在存在白介素和MHC II类抗原表达的情况下，用Xn肽文库测定所述T细胞克隆的增殖活性悬浮有DNA合成的细胞，所述细胞衍生自获得所述T细胞的个体，从而确定可以激活T细胞增殖的肽序列。

13. 发明申请

US20060002923A1 Recombinant anti-osteopontin antibody and use thereof 失效
标题翻译：重组抗骨桥蛋白抗体及其用途
公开(公告)号：US20060002923A1
公开(公告)日：2006-01-05
申请号：US10489866
申请日：2002-09-25
申请人： Toshimitsu Uede , Shigeyuki Kon , Nobuchika Yamamoto , Hirofumi Higuchi , Masaharu Torikai , Yoshiyuki Tokieda , Toshihiro Nakashima , Hiroaki Maeda
发明人： Toshimitsu Uede , Shigeyuki Kon , Nobuchika Yamamoto , Hirofumi Higuchi , Masaharu Torikai , Yoshiyuki Tokieda , Toshihiro Nakashima , Hiroaki Maeda
IPC分类号： A61K39/395 , C07H21/04 , C12P21/06 , C07K16/28 , C12N5/06
CPC分类号： C07K14/52 , A61K39/00 , A61K2039/505 , C07K16/24 , C07K16/2842 , C07K16/2848 , C07K2317/34
摘要： A recombinant antibody in which at least the constant regions in the heavy chain and the light chain have been converted into human-origin regions and which inhibits the binding of an integrin recognizing the RGD sequence to osteopontin or its fragment and inhibits the binding of an integrin recognizing the SVVYGLR sequence or a sequence corresponding thereto to osteopontin or its fragment. This antibody is useful as a remedy for autoimmune diseases and a remedy for rheumatism or rheumatoid arthritis. Thus, a method of treating autoimmune diseases, rheumatism or rheumatoid arthritis is provided. This osteopontin antibody is useful in a diagnostic for rheumatism and a method of diagnosing rheumatism too.
摘要翻译：重组抗体，其中至少重链和轻链中的恒定区已转化为人源区，并且抑制识别RGD序列的整联蛋白与骨桥蛋白或其片段的结合并抑制整联蛋白的结合识别SVVYGLR序列或与骨桥蛋白或其片段相应的序列。该抗体可用作自身免疫性疾病的补救剂和风湿病或类风湿性关节炎的治疗剂。因此，提供了治疗自身免疫疾病，风湿病或类风湿性关节炎的方法。该骨桥蛋白抗体可用于风湿病的诊断和风湿病的诊断方法。

14. 发明申请

US20050170451A1 Human type antihuman ige receptor antibody and fragment 失效
标题翻译：人类抗人类受体抗体和片段
公开(公告)号：US20050170451A1
公开(公告)日：2005-08-04
申请号：US10484206
申请日：2002-07-18
申请人： Kazuhisa Sugimura , Toshihiro Nakashima , Masaharu Torikai
发明人： Kazuhisa Sugimura , Toshihiro Nakashima , Masaharu Torikai
IPC分类号： A61P37/08 , C07K16/28 , C12N15/13 , C07H21/04 , C07K16/42
CPC分类号： C07K16/283 , A61K2039/505 , C07K2317/21 , C07K2317/622 , Y10S424/805
摘要： An antibody or an antibody fragment is provided that is efficacious for treating allergic diseases in which IgE is involved. A human antibody and a fragment thereof to a receptor (FcεRI) having high affinity to Fc portion of IgE was obtained using phage antibody display technique. The human anti-IgE receptor antibody and a fragment thereof of the invention has an activity to inhibit the binding between IgE and IgE receptor and hence is expected to be useful as a medicament for treating allergic diseases caused by the binding between IgE and IgE receptor.
摘要翻译：提供抗体或抗体片段，其对于治疗涉及IgE的过敏性疾病是有效的。使用噬菌体抗体展示技术，获得对IgE的Fc部分具有高亲和力的受体（FcepsilonRI）的人抗体及其片段。本发明的人抗IgE受体抗体及其片段具有抑制IgE和IgE受体之间结合的活性，因此预期可用作治疗由IgE和IgE受体结合引起的过敏性疾病的药物。

15. 外观设计

USD356594S Check printer and accounting machine 失效
公开(公告)号：USD356594S
公开(公告)日：1995-03-21
申请号：US10649
申请日：1993-07-14
申请人： Toshihiro Nakashima , Hideaki Sakamoto
设计人： Toshihiro Nakashima , Hideaki Sakamoto

16. 发明授权

US08603476B2 Humanized anti-human α9-integrin antibody 有权
标题翻译：人源化抗人α9整联蛋白抗体
公开(公告)号：US08603476B2
公开(公告)日：2013-12-10
申请号：US12812341
申请日：2009-01-09
申请人： Kenji Uehara , Hirofumi Higuchi , Toshihiro Nakashima , Daisuke Ishikawa , Nobuchika Yamamoto , Hirotada Fujita , Fumihiko Sakai
发明人： Kenji Uehara , Hirofumi Higuchi , Toshihiro Nakashima , Daisuke Ishikawa , Nobuchika Yamamoto , Hirotada Fujita , Fumihiko Sakai
IPC分类号： A61K39/395
CPC分类号： C07K16/2839 , C07K2317/24 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention provides a humanized anti-human α9 integrin antibody having improved activity and/or property as compared to a donor mouse anti-human α9 integrin antibody, namely, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:11 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:13 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:15 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:9, and a means for the prophylaxis or treatment of various diseases involving human α9 integrin in the pathogenesis, which uses the antibody.
摘要翻译：本发明提供与供体小鼠抗人α9整联蛋白抗体相比具有改善的活性和/或性质的人源化抗人α9整联蛋白抗体，即包含重链可变区的人源化抗人α9整联蛋白抗体，其包含的SEQ ID NO：11所示的氨基酸序列和由SEQ ID NO：17所示的氨基酸序列组成的轻链可变区，含有重链可变区的人源化抗人α9整联蛋白抗体包含由由SEQ ID NO：13所示的氨基酸序列和由SEQ ID NO：17所示的氨基酸序列组成的轻链可变区，含有重链可变区的人源化抗人α9整联蛋白抗体由SEQ ID NO：15所示的氨基酸序列和由SEQ ID NO：9所示的氨基酸序列组成的轻链可变区，以及预防或治疗涉及人类α9整联蛋白在发病机制中使用抗体。

17. 外观设计

USD669534S1 Electronic whiteboard 有权
公开(公告)号：USD669534S1
公开(公告)日：2012-10-23
申请号：US29416907
申请日：2012-03-28
申请人： Toshihiro Nakashima
设计人： Toshihiro Nakashima

18. 发明申请

US20110117602A1 HUMAN ANTIBODY CAPABLE OF INDUCING APOPTOSIS 审中-公开
标题翻译：人类抗体可诱导疫苗
公开(公告)号：US20110117602A1
公开(公告)日：2011-05-19
申请号：US12743739
申请日：2008-11-18
申请人： Yuji Ito , Masanori Baba , Naomichi Arima , Yasuo Suda , Toshihiro Nakashima , Masaharu Torikai
发明人： Yuji Ito , Masanori Baba , Naomichi Arima , Yasuo Suda , Toshihiro Nakashima , Masaharu Torikai
IPC分类号： C07K16/30 , C07H21/04 , C12N15/63 , C12P21/00
CPC分类号： C07K16/005 , C07K16/2833 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/73 , G01N33/57484
摘要： A human antibody that has a specific reactivity with multiple tumor cell lines including ATL cells and possesses both safety and therapeutic efficacy and a fragment of said antibody are provided. A human antibody and a fragment of said antibody that may recognize HLA-DR β chain expressed on the surface of tumor cells were obtained. In particular, it was found that a dimer of scFv (diabody) of said antibody may induce potent apoptosis in cells expressing the HLA-DR β chain. The antibody and a fragment of said antibody obtained in accordance with the present invention are useful for a detection reagent, a diagnostic and a medicament for protection or treatment of cancers including ATL and/or viral infectious diseases.
摘要翻译：提供了与多种肿瘤细胞系（包括ATL细胞）具有特异性反应性并具有安全性和治疗功效以及所述抗体片段的人类抗体。可以识别HLA-DR和bgr的人抗体和所述抗体的片段; 获得在肿瘤细胞表面表达的链。特别地，发现所述抗体的scFv（双抗体）的二聚体可能在表达HLA-DR和bgr的细胞中诱导有效的凋亡; 链。根据本发明获得的抗体和所述抗体的片段可用于检测试剂，诊断剂和用于保护或治疗包括ATL和/或病毒感染性疾病的癌症的药物。

19. 发明申请

US20090053212A1 HUMANIZED ANTI-HUMAN OSTEOPONTIN ANTIBODY 失效
标题翻译：人类抗人类骨质疏松症抗体
公开(公告)号：US20090053212A1
公开(公告)日：2009-02-26
申请号：US11755671
申请日：2007-05-30
申请人： Nobuchika Yamamoto , Fumihiko Sakai , Hirofumi Higuchi , Masaharu Torikai , Toshihiro Nakashima
发明人： Nobuchika Yamamoto , Fumihiko Sakai , Hirofumi Higuchi , Masaharu Torikai , Toshihiro Nakashima
IPC分类号： A61K39/395 , C07K16/18 , C07H21/04 , C12N15/64 , A61P37/06 , C12N1/21 , C12P21/00
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/24 , C07K2317/56
摘要： The present invention provides a humanized anti-human osteopontin antibody having better activities (antigen binding activity, leukocyte migration inhibitory activity and the like) and/or stability (resistance to heat, low-pH conditions, denaturants and the like) than those of conventional anti-human osteopontin antibodies.
摘要翻译：本发明提供具有比常规的更好的活性（抗原结合活性，白细胞迁移抑制活性等）和/或稳定性（耐热，低pH条件，变性剂等）的人源化抗人骨桥蛋白抗体抗人骨桥蛋白抗体。

20. 外观设计

USD575764S1 Intercom 有权
标题翻译：对讲机
公开(公告)号：USD575764S1
公开(公告)日：2008-08-26
申请号：US29297589
申请日：2007-11-14
申请人： Toshihiro Nakashima
设计人： Toshihiro Nakashima

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式